Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults
Information source: Massachusetts General Hospital
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: OROS methylphenidate hydrochloride (Drug); methylphenidate hydrochloride (Drug)
Phase: Phase 3
Status: Not yet recruiting
Sponsored by: Massachusetts General Hospital Official(s) and/or principal investigator(s):
Thomas Spencer, MD, Principal Investigator, Affiliation: Massachusetts General Hospital
Overall contact:
Meghan Dougherty, BS, Phone: 617-503-1051, Email: mdougherty2@partners.org
Summary
There are two specific aims of this study. The first is to document the pharmacokinetics of
dopamine transporter (DAT) receptor occupancy of repeated administration of orally
administered, therapeutic doses of a short immediate release-methylphenidate hydrochloride
(IR-MPH) and a long-acting formulation of MPH (OROS-MPH) using positron emission tomography
(PET) scanning with C-11 altropane as the ligand. The investigators hypothesize that
central nervous system (CNS) DAT occupancy of the OROS-MPH to IR-MPH sequence will be
greater than that of IR-MPH to OROS-MPH sequence at 5 hours after the initial administration
and that the CNS DAT occupancy of the other two formulations will be intermediate.
The second aim of this study is to assess whether the abuse liability potential of delayed,
repeated administrations of different formulations of MPH is moderated by the oral delivery
system in which a delivery system with slower onset may be safer than one with more rapid
early release.
Clinical Details
Official title: A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy of Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults
Study design: Randomized, Open Label, Historical Control, Crossover Assignment, Pharmacokinetics Study
Primary outcome: The DAT receptor occupancy of OROS MPH and MPH IR using PET scanning with C-11 altropane. Objective measures also provided by d and l ritalinic acid and methylphenidate levels at pre-dose, hour 4, 5 and 6.
Detailed description:
ROS-MPH's pharmacokinetic profile uses an increasing delivery of MPH over the day (ascending
pharmacokinetic curve). It was designed to replace IR-MPH TID treatment. The main target of
MPH in the brain is the dopamine transporter (DAT). We have an exquisitely sensitive
methodology to measure DAT occupancy using C-11 Altropane and Positron Emission Tomography
(PET). The time course of decay of the C-11 Altropane permits repeated imaging, thus
allowing documentation of the pharmacokinetics of DAT receptor occupancy.
We will test all combinations of initial administration and then delayed (repeated)
administration of the two formulations: IR-MPH to IR-MPH; IR-MPH to OROS-MPH; OROS-MPH to
IR-MPH; and OROS-MPH to OROS-MPH.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Signed written informed consent to participate in the study
2. Age: 18 - 55
3. If female, non-pregnant, non-nursing, using an adequate form of birth control or a
negative plasma pregnancy test
4. Supine and standing blood pressure within the range 110/60 to 150/90 mmHg
5. Heart rate, after resting for 5 minutes, within the range 46-90 beats/min
6. Subjects who are within 20% of the ideal weight for height
7. Right handed
Exclusion Criteria:
1. Subjects with marked anxiety, tension, and agitation since the drug may aggravate
these symptoms
2. Subjects with known hypersensitivity to methylphenidate or other components of
Concerta or Ritalin
3. Subjects with glaucoma
4. Subjects with motor tics or with a family history or diagnosis of Tourette's syndrome
5. Subjects treated with monoamine oxidase inhibitors (MAOIs) or within 14 days of
discontinuation of treatment with MAOIs
6. Diagnosis of any psychotic disorder, bipolar disorder, severe depression, severe
anxiety, or autism. Subjects with mild mood, oppositional, conduct, and anxiety
disorders may be permitted to participate if considered appropriate by the
investigator.
7. Scores of Baseline Scales:
- Hamilton Depression Scale > 17 (out of a possible 67 on the 21-item scale)
(Hamilton 1960)
- Beck Depression Inventory > 19 (out of a possible 63 on the 21-item scale)
(Beck et al 1961)
- Hamilton Anxiety Scale > 21 (out of a possible 56 on the 14-item scale)
(Hamilton 1959)
8. Diagnosis of ADHD (attention deficit hyperactivity disorder)
9. History of head trauma with loss of consciousness, organic brain disorders, seizures,
or neurosurgical intervention
10. Any clinically significant chronic medical condition, in the judgment of the
investigator
11. Mental impairment as evidenced by an intelligence quotient (I. Q.) < 75
12. Exposure to dopamine receptor antagonists within the previous three (3) months
13. Exposure to radiopharmaceuticals within four (4) weeks prior to PET scan
14. Subjects receiving psychotropic medication
15. Any clinically significant abnormality in the screening laboratory tests, vital
signs, or 12-lead ECG (electrocardiogram), outside of normal limits
16. Any woman of childbearing potential who is seeking to become pregnant or suspects
that she may be pregnant
17. Subjects with a known recent history (within the past six [6] months) of illicit drug
or alcohol dependence
Locations and Contacts
Meghan Dougherty, BS, Phone: 617-503-1051, Email: mdougherty2@partners.org
Massachusetts General Hospital, Cambridge, Massachusetts 02138, United States
Additional Information
Last updated: August 27, 2007
|
